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Background: The aim of this histomorphometric study was to assess the bone regeneration potential of beta-tri-
calcium phosphate with fibronectin (β-TCP-Fn) in critical-sized defects (CSDs) in rats calvarial, to know whether 
Fn improves the new bone formation in a short time scope.
Material and Methods: CSDs were created in 30 Sprague Dawley rats, and divided into four groups (2 or 6 weeks 
of healing) and type of filling (β-TCP-Fn, β-TCP, empty control). Variables studied were augmented area (AA), 
gained tissue (GT), mineralized/non mineralized bone matrix (MBM/NMT) and bone substitute (BS).
Results: 60 samples at 2 and six weeks were evaluated. AA was higher for treatment groups comparing to controls 
(p < 0.001) and significant decrease in BS area in the β-TCP-Fn group from 2 to 6 weeks (p = 0.031). GT was 
higher in the β-TCP-Fn group than in the controls expressed in % (p = 0.028) and in mm2 (p = 0.011), specially at 
two weeks (p=0.056).
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Introduction
The outcomes of dental implant treatment are high but 
compromised when there are alveolar bone defects.  In 
these cases, regeneration procedures are frequently re-
quired before or at the time of implant placement.
Autogenous bone grafts are still considered as the gold 
standard due to their biological properties (1). However, 
the increased morbidity, the limited amount of tissue 
graft available from the donor site and a high resorp-
tion rate lead to use allogenic, xenogenic or alloplastic 
materials as alternatives (2-5).
Alloplastic material, such as, hydroxyapatite (HA) and 
beta-tricalcium phosphate (β-TCP) have been widely 
studied and can be used instead of bone grafts due to 
its excellent biocompatibility and osteoconductivity. 
Several experimental studies have evaluated the physi-
cal properties and bone regeneration (BR) effects of HA 
and β-TCP (6-9).
In recent years, extensive experimental research has fo-
cused to accelerate BR (10-13) and tissue engineering 
using combinations of cells, scaffolds and bioactive fac-
tors to treat skeletal defects (14-17). 
Fibronectin (Fn) is a glycoprotein of the extracellular 
matrix that promotes cell adhesion and differentia-
tion and has been used in combination with biomate-
rials for improving proliferation and differentiation of 
osteoblasts cultivated on composite scaffolds (16,17). 
Furthermore, it has been shown that anodized titanium 
implants treated with fibroblast growth factor-Fn also 
enhanced osseointegration (18).
A previous study has tested the bone regeneration poten-
tial of β-TCP-Fn with autologous adipose-derived stem 
cells (β- TCP-Fn-ADSCs) in CSDs of alveolar ridges in 
a dog model (19) and in dehiscence-type defects associ-
ated with dental implants (20). The use of ADSCs does 
not seem to improve the area of bone regeneration and 
bone-implant contact (BIC) and did not entail a signifi-
cant advantage as compared with β-TCP-Fn alone.
In other study in rats, β-TCP-Fn was not significantly 
more effective than β-TCP alone for improving the vol-
ume of regenerated bone in CSDs at 6 and 8 weeks, al-
though bone turnover was higher in the β-TCP-Fn and 
differences between the use of β-TCP-Fn or β-TCP were 
observed at 8 weeks (4.25 [1.39] mm2 and 2.38 [0.88] mm2 
respectively; P = 0.004) in terms of gained tissue (miner-
alized bone matrix plus bone graft). No other significant 
differences between both grafting groups were found (21).
The aim of this histomorphometric study was to assess 
BR potential of β-TCP with and without Fn (β-TCP-Fn) 
in a short time period (2 and 6 weeks) by comparing 
them with a control in calvarial CSDs in an experimen-
tal rat model, when all defects are covered by a native 
collagen barrier membrane (Fig. 1).
Conclusions: Both β-TCP biomaterials are effective as compared with bone defects left empty in maintaining the 
volume. GT in defects regeneration filed with β-TCP-Fn are significantly better in short healing time when compar-
ing with controls but not for β-TCP used alone in rats calvarial CSDs.
Key words: Bone regeneration, biomaterials, experimental design, histology.
It was hypothesized that β-TCP-Fn would improve bone 
formation as compared with β-TCP alone at 2 weeks in 
this experimental rat model.
Material and Methods
- Material
The coating process of Beta-tricalcium phosphate (β-TCP) 
99% pure (KeraOs®, Keramat, A Coruña, Spain), was the 
same previously reported for the authors (19-21).
Fig. 1: Histomorphometric analysis. Definition of the regions of in-
terest (ROI) for the digital tissue differentiation procedure. Original 
image (a). Using a digital pen, the proportions occupied by new min-
eralized bone matrix (MBM, yellow) and bone substitute (BS, grey) 
were coloured. Defect area region (DA) was defined as the area oc-
cupied by the bone extracted during the surgery. Firstly, the interface 
between new and pristine bone was detected, outlined and finally 
linked following the curvature of the skull with straight lines (black 
and blue polygons). The increase in the cortical thickness caused by 
periosteal reaction was avoided (b). Augmented area region (AA) 
was outlined (red polygon) following the surface of the DA occupied 
by MBM and BS. The image analysis software calculated the area of 
MBM and BS within the AA. Percentage of graft in contact with new 
bone within the AA was manually determined using a digital pen (c). 
Magnification x40. Lévai-Laczkó staining.
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- Study design
The present reporting of in vivo animal experiment fol-
lowed the ARRIVE guidelines (22). Animal procedures 
were approved by the Ethics Committee on Animal 
Research (CEEA 346-12) of the University of Barce-
lona, Barcelona (Spain). Thirty male ex-reproductive 
Sprague Dawley rats (250-300g, 14 weeks’ old) were 
included in a prospective controlled study.
- Surgical protocol
The surgical protocol of this experimental study was 
previously described in detail by Escoda-Francolí et al. 
(21). Briefly, after the animals were anesthetized a cranial 
cutaneous incision was done in an antero-posterior direc-
tion. When calvarial bone was exposed, two bicortical 
cirtical-sized defects were created using a trephine bur 
of 5 mm of external diameter in both parietals. Out of 
30 defects, half of these were filled with material (β-TCP 
or β-TCP-Fn) and 30 were left empty as controls in the 
contralateral side. All defects were covered with a native 
bovine collagen membrane (Collagen-Klee®, Medical 
Biomaterials Products GmbH, Neustadt, Glewe, Germa-
ny), and the surgical field was closed by primary intent.
Finally, four study groups were obtained as follows: 
β-TCP-Fn/2 weeks, β-TCP/2 weeks, β-TCP-Fn/6 weeks, 
β-TCP/6 weeks.
- Histological preparation and histomorphometrical 
analysis
Histological samples of the skull portion surround-
ing the defect and the histomorphometric studies were 
performed by an experienced investigator (FM) who 
was blinded to the experiment were prepared follow-
ing guidelines previously published as in previous pub-
lished studies (19-21).
For each central section, the following variables were 
assessed (23) (Fig. 2):
1. Defect area diameter or former defect in mm (de-
scriptive variable).
2. Target Area (TA): surface occupied by bone ex-
pressed as mm2 (descriptive variable).
3. Augmented Area (AA): mineralized bone matrix 
and non-mineralized tissue and/or bone substitute ex-
pressed as mm2 and percentage of the AA within the TA 
(primary outcome variable).
4. Mineralized Bone Matrix (MBM): according to the 
recommendations of the American Society for Bone 
and Mineral Research (ASBMR) to standardize bone 
histomorphometric nomenclature (24), was defined as 
the mineralized tissue within AA expressed as mm2 and 
percentage.
5. Bone Substitute (BS): remaining graft particles with-
in AA expressed as mm2 and percentage.
6. Gained tissue (GT): total volume of MBM expressed 
as mm2 and percentage.
7. Graft Perimeter (GP): continuous line forming the 
boundary of the graft in TA expressed as mm.
8. Graft Surface to MBM (GS-MBM): the surface frac-
tion of RBS in contact with newly formed MBM ex-
pressed as percentage.
Fig. 2: Representative images of the defects filled with TCP, TCP-Fn and control at 2 and 6 
weeks. One week before sacrificing the animals, they received a dose of fluorochrome (tetra-
cycline) subcutaneously (right side images obtained with different wavelength filters). It can 
be observed differences between the control and the treated sites concerning the new miner-
alized bone and the presence of graft material. Lévai-Laczkó staining is able to differenciate 
new and old mineralized bone (new bone intense violet-blue, old paler tone). Bone substitute 
is shown in grey. Magnification x40.
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- Statistical analysis
The specimens’ characteristics were calculated as 
absolute and relative frequencies for categorical out-
comes. Normality of scale variables was explored us-
ing the Shapiro-Wilk test and through the visual anal-
ysis of the P-P plot and box plot.  Where normality 
was rejected, the interquartile range (IQR) and median 
were calculated. Where distribution was compatible 
with normality, the mean and standard deviation (SD) 
were used.
To compare the treatments (β-TCP-Fn, β-TCP or con-
trol) and to analyze the effect of time (2 or 6 weeks) and 
the interaction between these two variables, a mixed 
model was used considering the animal as a random 
factor. All models were validated qualitatively explor-
ing graphically the distribution of the residuals. For 
each follow-up time, pairwise comparisons between 
groups were performed.
The statistical analysis was carried out with the R soft-
ware v3.1.2 (Development Core Team 2008). The level 
of significance was set at p <0.05, using Tukey’s correc-
tion for multiplicity of contrasts.
Results
All rats were treated without registering any deviation 
from the protocol. Therefore, 30 animals were studied.
Histomorphometric analysis was performed in 60 sam-
ples, 30 collected at 2 weeks and 30 at 6 weeks. There 
were 15 (25.0%) samples in the β-TCP-Fn group (8 col-
lected at 2 weeks and 7 at 6 weeks), 15 (25.0%) in the 
β-TCP group (7 collected at 2 weeks and 8 at 6 weeks) 
and 30 (50%) in the untreated controls (15 collected at 2 
weeks and 15 at 6 weeks).
The mean (SD) diameter of the bone defect was 4.55 
[0.42] mm and comparable regarding treatment groups 
(p = 0.251) and weeks (p = 0.631). The mean target area 
was 4.35 [0.68] mm2, with significant differences (p = 
0.019) between β-TCP and controls (4.59 [0.66] vs. 4.16 
[0.64] mm2; p = 0.030; Table 1).
- AA
Significant differences between the three study groups 
were found, with significantly higher mean values for 
the two treatment groups (β-TCP-Fn and β-TCP) when 
compared to controls (77.5% [7.9] and 80.0% [14.9], re-
spectively, vs. 19.8% [17.5]; p < 0.001; Table 1). Also, at 
2 and 6 weeks, the AA was significantly higher in the 
two grafted treatment groups than in the controls (Table 
1, Fig. 3). An increase in AA was observed between 2 to 
6 weeks, especially in the β-TCP (from 69.3% to 89.3%; 
p < 0.001; Table 1) and control groups (from 12.3% to 
27.3%; p < 0.001; Table 1). It is important to note that 
after two weeks the defects filled with β-TCP-Fn have a 
higher AA than those filled in with β-TCP (75.03 [8.93] 
vs. 69.31 [14.20]) which is congruent with a faster in-
crease in bone formation.
- MBM
In relation to the effect of the graft materials in the MBM, 
no significant differences were found in absolute (mm2) 
nor relative (%) terms between the treatment groups and 
the controls (Table 1). Although a significant increase in 
MBM was observed from 2 to 6 weeks in all the study 
groups, the magnitude of the change was greater in the 
active groups than in the controls (β-TCP-Fn from 0.21 
[0.32] mm2 to 0.71 [0.51] mm2 and 1.4% [1.4] to 16.3% 
[9.8]; β-TCP from 0.06 [0.05] mm2 to 0.81 [0.55] mm2 
and 2.5% [3.5] to 16.3% [11.11]; controls from 0.20 
[0.18] mm2 to 0.62 [0.53] mm2 and 5.0% [4.4] to 15.3% 
[11.9]; Table 1). Again, MBM was greater at 2 weeks for 
β-TCP-Fn in mm2 and % but very similar at 6 weeks.
- Residual BS (RBS)
The percentage of bone substitute within the target 
area at 2 weeks in the two active treatment groups was 
significantly higher in the β-TCP-Fn (48.7% [5.7]) than 
in the β-TCP group (39.3% [7.7]; p = 0.040; Table 1). 
Similar results were obtained when BS was expressed 
as absolute area (mm2). There was a significant trend for 
a decrease in BS area in the β-TCP-Fn group from 2 to 6 
weeks (2.24 [0.58] mm2 and 1.70 [0.41] mm2; p = 0.031). 
- Gained tissue (GT)
Mean of GT expressed in percentage (MBM and resid-
ual BS) within the target area was significantly higher 
in the β-TCP-Fn group than in the controls (p = 0.028; 
Table 1). When GT was expressed as absolute area 
(mm2), the same statistical differences were obtained 
when comparing β-TCP-Fn group to controls was seen 
(p = 0.011; Table 1). At two weeks there is a tendency to 
a better result in terms of GT expressed in percentage 
for β-TCP-Fn vs. controls at two weeks (p=0.056).
Fig. 3: Percentage of augmented area (AA) within the target area 
by treatment groups and study periods (data expressed as mean and 
standard deviation); *#statistically significant differences for the 
comparison of β-TCP-Fn and β-TCP vs. controls.
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Overall 4.65 (0.41) 4.64 (0.39) 4.46 (0.43) 0.627 0.989 0.332 0.416
2 weeks 4.68 (0.50) 4.61 (0.33) 4.51 (0.54) 0.411 0.923 0.627 0.895
6 weeks 4.62 (0.31) 4.66 (0.46) 4.41 (0.29) 0.212 0.981 0.513 0.361 0.776 0.780 0.496
Target area (mm2)
Overall 4.49 (0.73) 4.59 (0.66) 4.16 (0.64) 0.019 0.716 0.226 0.030
2 weeks 4.60 (0.92) 4.42 (0.53) 4.15 (0.61) 0.085 0.994 0.304 0.284
6 weeks 4.36 (0.48) 4.74 (0.76) 4.18 (0.68) 0.137 0.580 0.640 0.072 0.754 0.601 0.932
Augmented area (mm2)
Overall 3.48 (0.68) 3.70 (0.96) 0.82 (0.78) <0.001 0.817 <0.001 <0.001
2 weeks 3.48 (0.93) 3.08 (0.72) 0.49 (0.40) <0.001 0.584 <0.001 <0.001
6 weeks 3.49 (0.28) 4.25 (0.82) 1.15 (0.94) <0.001 0.171 <0.001 <0.001 0.900 0.006 0.021
Augmented area within target area (%)
Overall 77.49 (7.93) 79.98 (14.85) 19.79 (17.52) <0.001 0.939 <0.001 <0.001
2 weeks 75.03 (8.93) 69.31 (14.20) 12.31 (9.98) <0.001 0.688 <0.001 <0.001
6 weeks 80.30 (6.05) 89.31 (7.40) 27.26 (20.40) <0.001 0.404 <0.001 <0.001 0.452 0.008 0.005
Mineralized bone matrix (mm2)
Overall 0.45 (0.48) 0.46 (0.55) 0.41 (0.44) 0.902 0.936 0.852 0.991
2 weeks 0.21 (0.32) 0.06 (0.05) 0.20 (0.18) 0.419 0.787 0.998 0.759
6 weeks 0.71 (0.51) 0.81 (0.55) 0.62 (0.53) 0.741 0.984 0.774 0.626 0.015 0.002 0.007
Mineralized bone matrix (%)
Overall 8.90 (10.47) 9.34 (10.35) 10.12 (10.22) 0.890 0.965 0.969 0.852
2 weeks 2.48 (3.50) 1.43 (1.38) 5.00 (4.41) 0.555 0.979 0.745 0.626
6 weeks 16.25 (11.11) 16.27 (9.75) 15.25 (11.86) 0.968 0.986 0.927 0.980 0.003 0.003 0.002
Bone substitute (mm2)
Overall 1.99 (0.56) 1.79 (0.40) NA 0.289 0.289 NA NA
2 weeks 2.24 (0.58) 1.74 (0.40) NA 0.046 0.046 NA NA
6 weeks 1.70 (0.41) 1.83 (0.42) NA 0.579 0.579 NA NA 0.031 0.719 NA
Bone substitute (%)
Overall 44.55 (9.99) 39.11 (7.42) NA 0.110 0.110 NA NA
2 weeks 48.72 (5.65) 39.25 (7.71) NA 0.040 0.040 NA NA
6 weeks 39.78 (12.08) 38.99 (7.70) NA 0.857 0.857 NA NA 0.052 0.953 NA
Graft perimeter in target area (mm)
Overall 12.31 (2.87) 12.19 (4.95) NA 0.918 0.918 NA NA
2 weeks 13.23 (3.07) 13.58 (3.83) NA 0.855 0.855 NA NA
6 weeks 11.27 (2.41) 11.47 (4.86) NA 0.881 0.881 NA NA 0.316 0.307 NA
Graft Surface to Mineralized Bone Matrix contact (%)
Overall 9.85 (15.91) 13.74 (16.41) NA 0.393 0.393 NA NA
2 weeks 1.77 (3.88) 0.57 (1.08) NA 0.851 0.851 NA NA
6 weeks 19.07 (19.67) 25.27 (14.58) NA 0.339 0.339 NA NA 0.012 0.001 NA
Gained tissue (mm2)
Overall 1.98 (0.92) 1.42 (0.98) 1.05 (1.18) 0.037 0.316 0.028 0.561
2 weeks 1.87 (0.95) 1.19 (1.00) 0.80 (1.11) 0.103 0.455 0.078 0.709
6 weeks 2.11 (0.94) 1.62 (0.98) 1.31 (1.22) 0.312 0.657 0.250 0.785 0.661 0.444 0.205
Gained tissue (%)
Overall 44.52 (19.57) 32.22 (20.98) 23.03 (23.36) 0.016 0.261 0.011 0.420
2 weeks 40.97 (17.59) 27.03 (22.18) 17.66 (22.68) 0.079 0.447 0.056 0.624
6 weeks 48.58 (22.29) 36.75 (20.19) 28.39 (23.53) 0.181 0.557 0.129 0.662 0.508 0.399 0.191
Note: p-values from the correspondent mixed model considering week, treatment and their interaction as fixed effects and animal as a random 
factor. Tukey’s correction for multiple testing was applied.
Table 1: Results of histomorphometric variables in the three study groups. Data expressed as mean (SD); NA: not applicable.
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This event is not observed for β-TCP alone. No differ-
ences between β-TCP-Fn and β-TCP were observed in 
terms of GT (p = 0.316; Table 1).
- Graft perimeter
The overall GP amounted to 12.31 (2.87) mm for β -TCP-
Fn and 12.19 (4.95) mm for β-TCP, due to the similar 
amount of particles inserted into the defects. Although 
there were no statistically significant differences between 
the grafted defects with β-TCP-Fn or β-TCP, a slight re-
duction in GP was noticed in both of the active groups 
(Table 1). 
- Graft Surface to MBM contact
When assessing the GS-MBM, the highest mean values 
were reached for the β-TCP group, but differences were 
not statistically significant (p > 0.05; Table 1). Within-
group comparisons there is a significant increase in 
GS-MBM between 2 and 6 weeks in CSDs treated with 
β-TCP-Fn (from 1.77 [3.88] % to 19.07 [19.67] %; p = 
0.012; Table 1) and β-TCP (from 0.57 [1.08] % to 25.27 
[14.58] %; p = 0.001; Table 1).
Discussion
This study shows that the addition of fibronectin to 
β-TCP grafted material was effective to improve bone 
regeneration in calvarial CSDs in a rat model respect to 
the negative controls in some histomorphometric param-
eters.  GT, defined as MBM plus residual BS, measured 
in mm2 and as a percentage of the target area obtained 
the best result when compared β-TCP-Fn to the controls, 
specially at short time (two weeks of healing). Mean of 
GT within the target area was significantly higher in the 
β-TCP-Fn group than in the controls (p=0.028). When 
GT was expressed as absolute area (mm2), the same 
statistical differences were obtained when comparing 
β-TCP-Fn group to controls (p=0.011) and there is an al-
most statistically significant difference in favor related 
to the percentage at two weeks (p=0.056).
These results at that time point (2 weeks), could be a 
consequence of two factors: a greater amount of MBM 
in mm2 (2.24 [0.58]) and in percentage (2.48 [3.50]) and 
a significantly greater amount of BS in mm2 (2.24 [0.58]) 
and in percentage (48.72 [5.65]) in contrast with β-TCP 
alone for the same parameters ((0.06 [0.05],  1.43[1.38], 
1.74 [0.40], 39.25 [7.71] respectively).
In return, looking MBM results at 6 weeks, it can be ob-
served a change in the behavior of the alloplastic modi-
fied material having almost de same figure for the two 
test groups both in mm2 (0.71 [0.51] for β-TCP-Fn vs. 
0.81 [0.55]) and in percentage (16.25 [11.11] for β-TCP-
Fn vs. 16.27 [9.75]), possibly as a consequence of a faster 
mineralization when Fn is added to β-TCP, and a greater 
ratio of resorption of the bone substitute throughout the 
experimentation period as Rojbani et al. observed using 
β-TCP coated with simvastatin (8). These results can be 
interesting in terms of clinical applicability.
Respect of the AA within the CSDs, the amount of 
bone regenerated was similar in the study groups inde-
pendently of the time period (p=0.817), but -Fn group 
maintain the same volume in mm2 along the time (3.48 
[0.93] at 2 weeks, 3.49 [0.28] at 4 weeks) and conversely 
β-TCP group reached this volume progressively in-
creasing.  β-TCP-Fn seems more effective respect to 
the volume maintenance since the grafting time. In a 
previous study, the same variables where evaluated but 
with longer healing time (6 and 8 weeks). At 8 weeks 
MBM in mm2 was observed a significant difference in 
favor of β-TPC-Fn respect to the β-TPC alone (p=0.04). 
Changes of bone regeneration according to materials 
used and time of analysis also suggest a more favorable 
effect of β-TCP-Fn as the percentage of MBM in the 
target area was further increased from week 6 to week 
8 (p=0.067) (21).
Only Calciolari et al. (25) studying collagen membranes 
degradation for bone regeneration purposes in calvarial 
CSDs, used shortest time periods to evaluate the thick-
ness and histological events of the membrane but not the 
quality or quantity of the regenerated bone (7, 14 and 
30 days) as our experimental model. Ramalingam et al. 
(26) compare guide bone regeneration using β-TPC and 
collagen membrane in an in vivo model with micro-
CT of 3.3. diameter calvarial defects at 2, 4, 6 and 10 
weeks but doesn’t retrieve histological data until the 
10th week, when finally sacrificed the rats. Kostopoulos 
& Karring (27) analyzed osseous regeneration in 2x3 
mandibular bone defects covered with a polyhidroxy-
butyrate acid membrane at 7, 15, 30, 90 and 180 days in 
terms of histologic composition and percentage of filing 
of the original defect specifying that at 1-month con-
trols were completely repaired. Then, few possibilities 
of comparison could be done at 2 weeks period amongst 
de effects of other filling materials for bone regenera-
tion and β-TCP-Fn.  Most of the authors evaluates the 
samples between 4, 6, 8, 10 weeks (28-31). This short 
time experimental period of two weeks also guarantees 
that the spontaneous healing of the defect does not oc-
cur, as it was in some cases, using equal size defects as 
in a previous study (21).
Microporosity, crystallinity and size of the β-TCP parti-
cle seem crucial to provide an optimal structure for vas-
cular growth and bone formation. Microporosity (pore 
size) < 10 µm increases macromolecule adhesion and 
favor fluid penetration, although a highly porous β-TCP 
material (> 100 µm) also supported new bone forma-
tion (32). On the other hand, reducing the size of β-TCP 
granules to nanometers may also contribute to induce 
higher porosity and larger specific surfaces, leading to 
an improved regenerative effect (7). In our study, the 
pore size of KeraOs® was between 100-250 µm, but fu-
ture studies should be focused on assessment of the per-
formance of β-TCP materials with smaller particle size.
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Fibronectin has been used to stimulate mineralization 
and cell adhesion in tricalcium phosphate scaffolds, re-
sulting in early differentiation of osteoblasts (16). In a 
novel multilayered chitosan-hydroxyapatite composite, 
the addition of Fn (25 or 50 µg/ml) improved osteoblast 
cell adhesion and proliferation, demonstrating the po-
tential of fibronectin for improving the quality of this 
material as a bone graft (17). In our study the concentra-
tion of fibronectin is coated to a 1 gr of a β-TCP scaffold 
but 10 µg/ml. Comparisons about concentrations cannot 
be calculated because the data in the study cited (17) are 
expressed in mm3 for the scaffold and in 10 µl/ml for 
fibronectin.
Is suggested in an in vitro study using a Fn-derived oli-
gopeptide, that fibronectin also induces osteoblast dif-
ferentiation mediated by BMP-2 and can be used as a 
therapeutic biomolecule to facilitate even periodontal 
regeneration (33). Other attempts to improve β-TCP 
scaffolds has been done with simvastatin that seems to 
stimulate BMP-2 expression of osteoblasts, combined 
with three different calcium phosphate biomaterials 
(α-TCP, β-TCP and hydroxyapatite) in a rat calvarial de-
fect model (8). The results showed that simvastatin also 
affected the α-TCP and β-TCP degradation, and espe-
cially when combined to α-TCP, which showed a higher 
degradation rate allowing more bone formation (8,34).
Other associations to β-TCP are: growth factors (11,35) 
dental pulp stem cells (14,15), with inconsistent results, 
adipose stem cells (19,20), BMP-2 that did not substan-
tially changed the osteoconductive properties of the 
biomaterials grafted as compared with TCP alone (12), 
BMP-2 in 3D printed polycaprolactone/ β-TCP plus 
decellularized extracellular matrix with significant im-
provement (p<0.01) when compared with controls (29).
In the present study, calvarial defects in controls gained 
less volume than those in the remaining groups because 
grafts helped to maintain the original bonny space con-
firming previous research (21), being the AA in percent-
age of the target area 75.03 [8.93] for β-TCP-Fn, 69.31 
[14.20] for β-TCP and 12.31 [9.98] for controls  at two 
weeks (p=0.001), taking into account that also controls 
were covered with collagen membrane and, as it has 
been demonstrated, this treatment is a benefit for bone 
regeneration at an early stage giving enough time to the 
bone cells to refill the hard tissue defect (36).
Barrier membrane in our study did not influence to the 
ability to be an effective negative control allowing to 
obtain statistically significant results between the test 
and control groups at different times. Donos et al. (37) 
with a similar experimental model, concluded that the 
use of a barrier membrane alone has the same efficacy 
as the use of regeneration materials, nevertheless, the 
time of euthanasia of  the  experimental model was 16 
weeks, so it could be thought that CSDs 5 mm in diam-
eter was too little  for their study time, although it can 
be considered adequate in rat model for other periods. 
Even so, the authors conclude that the control’s heal-
ing occurred with a significant regeneration deficit in 
height (38).
Findings of the study should be interpreted taking into 
account some limitations. A potential source of bias re-
lated to the differences between individuals done by the 
size and thickness of the calvaria. This drawback was 
corrected by expression the results of histomorphomet-
ric variables as percentages of the target area.    
Regarding the bilateral 5 mm diameter for the CSDs, it 
seems sufficient to obtain relevant data (38). Although 
the design used allows reduce the risk of bias by having 
the tested material and the control in the same animal, 
it can be a risk in terms of contamination of the con-
trol defect (38) in our case, no one contaminated control 
sample was found in any group and any time.
Although no species fulfils the requirements of an ideal 
animal model, rodents are one of the best choices be-
cause they are easily available, easy to house and han-
dle. Also, a large number of studies on regeneration of 
bone defects published in the literature have been car-
ried out in rat models. In addition, the rat calvarial bone 
model allows establishing a standardized and reproduc-
ible defect.
The applicability of this findings could be interesting 
due to the maintenance of the bone volume pretended 
to regenerate and the faster mineralization of the tissue 
gained leading a safe and more predictable results when 
an osseous regeneration is necessary
 
Conclusions
With the limitations of this study, β-TCP with and with-
out fibronectin supposed an advantage in maintaining 
the volume regenerated, avoidance of soft tissue invad-
ing the hard tissue space and acceleration of the new 
bone formation process when compared with bone de-
fects left empty. 
Gained tissue in defects filled with β-TCP coated with 
fibronectin is significantly better when compared with 
controls this event is not confirmed for β-TCP used 
alone in rats calvarial CSDs.
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